New pill targets Hard-to-Treat cancers in 334-Patient trial
NCT ID NCT05005234
First seen Nov 17, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tested a drug called GFH925 in 334 people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal was to check the drug's safety, find the right dose, and see if it shrinks tumors in cancers like lung and colorectal cancer. Participants took the drug by mouth, and researchers monitored side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.